Argenx Will Discontinue Phase 3 UNITY Study Of Efgartigimod SC In Sjögren's Disease After IDMC Recommends Stopping For Futility At Interim Analysis; No New Safety Signals Identified
Share
Why It Matters
Argenx stopped testing a medicine for dry eye disease. The medicine was not working well enough to keep testing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.